In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Why Early-Stage Dealmaking is Hot

Executive Summary

Big Pharma is in-licensing increasing numbers of preclinical and Phase I compounds despite the fact that their own early-stage productivity is up. Their goal is to increase shots on goal; to pay for the ballooning costs, however, they're increasingly willing to share downstream rights for near-term help on expenses.

Related Content

The $100 Million IND
Trade Sales Trump IPOs, Even for Platforms
Curis Reformed: Unearthing Preclinical Value
Curis Reformed: Unearthing Preclinical Value
Making Licensing Pay
Making Licensing Pay
Theravance: Having Cake and Eating It
Pfizer/Angiosyn: Building Biotechs for Device-style Early M&A
Top Biotech Licensings of 2004
The Buzz at JP Morgan--Biopharma: New Models Wanted


Related Companies




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts